BioSpace News Archive

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV.

GC Genome Corporation, a leading diagnostics company, announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, May 31–June 4.

Innate Pharma SA, announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.

Modalis Therapeutics Corporation, a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the preprint paper titled “Efficient and durable gene activation by Cas9-mediated epigenome editing in vivo” on bioRxiv.

Valneva SE, a specialty vaccine company, reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

Sandoz, the global leader in generic and biosimilar medicines, announced net sales for the first quarter 2024.

BioVersys AG announced the expansion of its strategic collaboration with the global biopharma company GSK plc to accelerate the clinical development of alpibectir for the treatment of tuberculosis.

Neurogene Inc. announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome, which showed that NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately nine, six and three months post-dosing.

Design Therapeutics, Inc. announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient, announced that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024.